Melanoma & Skin Cancer

Relatlimab plus nivolumab did not improve RFS over nivolumab alone in resected stage III to IV melanoma, per the final phase 3 RELATIVITY-098 results.

Second-line lifileucel generated durable responses and survival signals in patients with advanced melanoma, according to a 5-year analysis.

Nivolumab plus relatlimab generated favorable intracranial responses in patients with advanced PD-(L)1-refractory melanoma with brain metastases.

The efficacy of relatlimab/nivolumab was consistent across patient subgroups vs ipilimumab/nivolumab in advanced melanoma.

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

Vincent Ma, MD, emphasizes the need for novel therapies for patients with melanoma who are refractory to or ineligible for standard checkpoint inhibition.

Vincent Ma, MD, discusses progress in the management of advanced-stage melanoma and the need for primary prevention during Skin Cancer Awareness Month.

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

Stergios Moschos, MD, discusses his approach to selecting from the available agents in metastatic melanoma after first-line PD-1 inhibition.

China’s NMPA has approved the sNDA for toripalimab as a first-line treatment for patients with unresectable or metastatic melanoma.

On April 4, 2025, a select group of international experts in dermatologic oncology participated in a live workshop to discuss treatment options in high-risk or locally advanced/metastatic melanoma and non-melanoma skin cancers in an evolving treatment landscape. Caroline Robert, MD, PhD, led the discussion, obtaining perspectives on the available evidence about immunotherapy options and insights into treatment preferences for high-risk cutaneous squamous cell carcinoma that is either locally advanced (laCSCC) or metastatic (mCSCC) and advanced/metastatic cutaneous melanoma.

Updated interim phase 2 data showed the clinical efficacy and safety of neoadjuvant darovasertib monotherapy in localized uveal melanoma.

Silmitasertib generated disease control in patients with locally advanced or metastatic basal cell carcinoma.

Single-dose neoadjuvant pembrolizumab was safe with no surgical delays and boosted MPR rates in resectable melanoma.

A federally funded research team is testing a new combination drug therapy that could both treat and prevent melanoma metastasis to the brain.

Moffitt Cancer Center researchers found a way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure.

Micro-array needles containing doxorubicin displayed safety and early activity in basal cell carcinoma of the skin.

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Teresa Petrella, MD, MHSc, FRCPC, discusses long-term data that inform the sequencing of immunotherapy and targeted therapies for frontline melanoma.

FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.

The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.

Tara C. Mitchell, MD, discusses considerations and lingering questions regarding pre- and post-operative management strategies in stage IIB/IIIC melanoma.

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

Nivolumab plus relatlimab did not improve recurrence-free survival vs nivolumab in resected stage III/IV melanoma.

The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.

Omid Hamid, MD, discusses therapies emerging in the squamous cell carcinoma treatment paradigm, including a novel cancer vaccine.

Marlana M. Orloff, MD, discusses optimal therapeutic approaches for patients with uveal melanoma that is rapidly progressing.

Mark Faries, MD, discusses how CAR T-cell and TCR cell therapies compare with TIL approaches in melanoma.